We are live on
!
Find out more
EAM
Eventide Asset Management Portfolio holdings
AUM
$6.05B
1-Year Est. Return
76.64%
This Fund
S&P 500
This Quarter
Est. Return
-16.98%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$4.68B
AUM Growth
-$1.71B
(-27%)
Cap. Flow
-$462M
Cap. Flow
% of AUM
-9.88%
Top 10 Holdings %
Top 10 Hldgs %
25.31%
Holding
149
New
16
Increased
23
Reduced
54
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Doximity
DOCS
|
+$59.6M |
| 2 |
GTM
ZoomInfo Technologies
GTM
|
+$19.8M |
| 3 |
CMS Energy
CMS
|
+$19.8M |
| 4 |
Guardant Health
GH
|
+$18.2M |
| 5 |
Cheniere Energy
LNG
|
+$15.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dynatrace
DT
|
+$112M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$64.6M |
| 3 |
SMAR
Smartsheet Inc.
SMAR
|
+$38.2M |
| 4 |
Roper Technologies
ROP
|
+$32.9M |
| 5 |
Lam Research
LRCX
|
+$31.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 35.3% |
| 2 | Technology | 26.13% |
| 3 | Industrials | 16.22% |
| 4 | Consumer Discretionary | 5.49% |
| 5 | Utilities | 5.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Synopsys
SNPS
$71.3B
| $17.1M | 0.36% |
56,157
-16,900
| -23% | -$5.1M |
|
77
Pentair
PNR
$10.6B
| $16M | 0.34% |
350,400
| – | – |
|
78
Yeti Holdings
YETI
$3.76B
| $16M | 0.34% |
369,000
| – | – |
|
79
Cognex
CGNX
$10.4B
| $15.3M | 0.33% |
359,000
| – | – |
|
80
Intuitive Surgical
ISRG
$126B
| $15.1M | 0.32% |
75,000
| – | – |
|
81
ADC Therapeutics
ADCT
$141M
| $14.9M | 0.32% |
1,879,959
-95,041
| -5% | -$899K |
|
82
Nurix Therapeutics
NRIX
$2.45B
| $14.6M | 0.31% |
1,154,000
-716,000
| -38% | -$8.12M |
|
|
BCYC
83
Bicycle Therapeutics
BCYC
$280M
| $14.3M | 0.31% |
853,800
-409,671
| -32% | -$8.64M |
|
84
Xenon Pharmaceuticals
XENE
$6.2B
| $14.3M | 0.31% |
+469,700
| New | +$14.2M |
|
85
Sutro Biopharma
STRO
$411M
| $14.1M | 0.3% |
270,898
| – | – |
|
86
KLA
KLAC
$236B
| $14M | 0.3% |
440,280
-234,000
| -35% | -$7.87M |
|
87
Annexon
ANNX
$863M
| $13.7M | 0.29% |
3,626,508
| – | – |
|
88
Sysco
SYY
$40.6B
| $13.7M | 0.29% |
161,298
| – | – |
|
|
AESC
89
DELISTED
The AES Corporation
AESC
| $13M | 0.28% |
151,100
| – | – |
|
90
CDW
CDW
$18.6B
| $13M | 0.28% |
+82,600
| New | +$13.9M |
|
91
Baxter International
BAX
$13.8B
| $12.8M | 0.27% |
+198,600
| New | +$14.4M |
|
|
VECT
92
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $12.6M | 0.27% |
2,339,044
| – | – |
|
93
Equity Lifestyle Properties
ELS
$12.7B
| $11.4M | 0.24% |
161,600
-66,600
| -29% | -$4.97M |
|
|
ICPT
94
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $11M | 0.24% |
800,000
| – | – |
|
95
IDEX
IEX
$17.3B
| $10.6M | 0.23% |
58,400
| – | – |
|
|
EPIX
96
DELISTED
ESSA Pharma
EPIX
| $10.6M | 0.23% |
3,365,568
-804,691
| -19% | -$4.5M |
|
97
Shoals Technologies Group
SHLS
$1.49B
| $10.2M | 0.22% |
620,832
| – | – |
|
|
APTV.PRA
98
DELISTED
Aptiv PLC 5.50% Series A Mandatory Convertible Preferred Shares
APTV.PRA
| $10M | 0.21% |
+94,500
| New | +$11.2M |
|
99
Pharvaris
PHVS
$2.37B
| $9.95M | 0.21% |
450,251
+147,632
| +49% | +$2.75M |
|
100
GXO Logistics
GXO
$5.8B
| $9.52M | 0.2% |
220,000
| – | – |
|
Similar funds
HPG
EMPI
RCG
JWBC
AAM
AA
CM
CIS
Eventide Asset Management's Q2 2022 Portfolio in Review
As of Q2 2022, Eventide Asset Management held 149 positions worth $4.68B, down 27% from $6.38B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Eventide Asset Management withdrew a net $462M in Q2 2022, closing 13 positions and reducing 54 holdings. Its most notable exit was Dynatrace, an estimated $112M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 33% a quarter earlier, followed by Technology and Industrials.
Against the trend, Eventide Asset Management opened a new position in Doximity worth $52.7M.
- Eventide Asset Management's largest Q2 2022 buy was Doximity: 1,512,602 shares worth $52.7M.
- Eventide Asset Management added most to ZoomInfo Technologies in Q2 2022, an estimated $19.8M increase.
- Eventide Asset Management's biggest Q2 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $64.6M.
- Eventide Asset Management fully exited Dynatrace in Q2 2022, selling an estimated $112M.
- Eventide Asset Management's ten largest holdings make up 25% of its $4.68B portfolio in Q2 2022.
- Eventide Asset Management opened 16 new positions and closed 13 in Q2 2022.
- Eventide Asset Management's portfolio value fell 27% quarter-over-quarter to $4.68B.
Based on Eventide Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.